Form 8-K - Current report:
SEC Accession No. 0001558370-24-015839
Filing Date
2024-11-18
Accepted
2024-11-18 08:35:23
Documents
18
Period of Report
2024-11-15
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrbo-20241115x8k.htm   iXBRL 8-K 51399
2 EX-3.1 nrbo-20241115xex3d1.htm EX-3.1 12894
3 EX-3.2 nrbo-20241115xex3d2.htm EX-3.2 176616
4 EX-99.1 nrbo-20241115xex99d1.htm EX-99.1 16299
5 GRAPHIC nrbo-20241115x8k001.jpg GRAPHIC 12152
6 GRAPHIC nrbo-20241115xex99d1001.jpg GRAPHIC 12945
  Complete submission text file 0001558370-24-015839.txt   480809

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrbo-20241115.xsd EX-101.SCH 3285
8 EX-101.LAB nrbo-20241115_lab.xml EX-101.LAB 16583
9 EX-101.PRE nrbo-20241115_pre.xml EX-101.PRE 10534
20 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20241115x8k_htm.xml XML 5109
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 241469832
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)